Table 45Summary of the Signs of Psoriasis (Scaling) by Visit for the Target Lesion (ITT Set)

% of patients
N at baselineBaselineWeek 2Week 4Week 6Week 8Week 12
Scaling (target lesion)
Study 301

HP/TAZ

N = 135

0 – None▬▬▬▬▬▬▬
1 – Minimum▬▬▬▬▬▬▬
2 – Mild▬▬▬▬▬▬▬
3 – Moderate▬▬▬▬▬▬▬
4 – Severe▬▬▬▬▬▬▬

Vehicle

N = 68

0 – None▬▬▬▬▬▬▬
1 – Minimum▬▬▬▬▬▬▬
2 – Mild▬▬▬▬▬▬▬
3 – Moderate▬▬▬▬▬▬▬
4 – Severe▬▬▬▬▬▬▬
Study 302

HP/TAZ

N = 141

0 – None▬▬▬▬▬▬▬
1 – Minimum▬▬▬▬▬▬▬
2 – Mild▬▬▬▬▬▬▬
3 – Moderate▬▬▬▬▬▬▬
4 – Severe▬▬▬▬▬▬▬
Vehicle N = 740 – None▬▬▬▬▬▬▬
1 – Minimum▬▬▬▬▬▬▬
2 – Mild▬▬▬▬▬▬▬
3 – Moderate▬▬▬▬▬▬▬
4 – Severe▬▬▬▬▬▬▬

HP/TAZ = halobetasol propionate and tazarotene; ITT = intention to treat.

Source: Clinical Study Reports for Study 30110 and Study 302.11

From: Appendix 3, Detailed Outcome Data

Cover of Clinical Review Report: Halobetasol Propionate and Tazarotene (Duobrii)
Clinical Review Report: Halobetasol Propionate and Tazarotene (Duobrii): (Bausch Health, Canada Inc.): Indication: Psoriasis, moderate-to-severe plaque [Internet].
Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.